Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders

The Lancet Neurology

Volumn 9, Issue 4, 2010, Pages 413-424

  Mantegazza, Massimo ^a,b   Curia, Giulia ^c   Biagini, Giuseppe ^d   Ragsdale, David S ^c   Avoli, Massimo ^c,e  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; FLECAINIDE; HARKOSERIDE; LAMOTRIGINE; PHENYTOIN; RILUZOLE; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL;

ABSENCE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; EPILEPSY; FOCAL EPILEPSY; GENE MUTATION; HUMAN; LENNOX GASTAUT SYNDROME; MIGRAINE; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; MYOCLONUS SEIZURE; NERVE CELL EXCITABILITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEIZURE; TONIC CLONIC SEIZURE;

ANIMALS; EPILEPSY; HUMANS; NERVOUS SYSTEM DISEASES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 77949300922     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70059-4     Document Type: Review

References (113)

1. Hille B. Ionic channels of excitable membranes (2001), Sinauer Associates Inc, Sunderland
2. + current in entorhinal cortex neurons. J Neurosci 19 (1999) 7334-7341
3. Crill W.E. Persistent sodium current in mammalian central neurons. Annu Rev Physiol 58 (1996) 349-362
4. Stafstrom C.E. Persistent sodium current and its role in epilepsy. Epilepsy Curr 7 (2007) 15-22
5. Mantegazza M., Yu F.H., Powell A.J., Clare J.J., Catterall W.A., and Scheuer T. Molecular determinants for modulation of persistent sodium current by G-protein βγ subunits. J Neurosci 25 (2005) 3341-3349
6. + channels. Proc Natl Acad Sci USA 105 (2008) 18994-18999
7. Stys P.K. General mechanisms of axonal damage and its prevention. J Neurol Sci 233 (2005) 3-13
8. Waxman S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 4 (2008) 159-169
9. Catterall W.A., Goldin A.L., and Waxman S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 (2005) 397-409
10. + channels by local anesthetics. Science 265 (1994) 1724-1728
11. + channel α subunit. J Biol Chem 276 (2001) 20-27
12. + channel α subunit in voltage-dependent gating and drug block. J Biol Chem 277 (2002) 35393-35401
13. Lipkind G.M., and Fozzard H.A. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol 68 (2005) 1611-1622
14. Mantegazza M., Yu F.H., Catterall W.A., and Scheuer T. Role of the C-terminal domain in inactivation of brain and cardiac sodium channels. Proc Natl Acad Sci USA 98 (2001) 15348-15353
15. v1.5 by interacting proteins. Trends Cardiovasc Med 15 (2005) 35-40
16. Goldin A.L. Mechanisms of sodium channel inactivation. Curr Opin Neurobiol 13 (2003) 284-290
17. Chen Y.H., Dale T.J., Romanos M.A., Whitaker W.R., Xie X.M., and Clare J.J. Cloning, distribution and functional analysis of the type III sodium channel from human brain. Eur J Neurosci 12 (2000) 4281-4289
18. Holland K.D., Kearney J.A., Glauser T.A., et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett 433 (2008) 65-70
19. Black J.A., Liu S., and Waxman S.G. Sodium channel activity modulates multiple functions in microglia. Glia 57 (2009) 1072-1081
20. + channels in glia: properties and possible functions. Trends Neurosci 19 (1996) 325-331
21. Káradóttir R., Hamilton N.B., Bakiri Y., and Attwell D. Spiking and nonspiking classes of oligodendrocyte precursor glia in CNS white matter. Nat Neurosci 11 (2008) 450-456
22. Steihhäuser C., and Seifert G. Glial membrane channels and receptors in epilepsy: impact for generation and spread of seizure activity. Eur J Pharmacol 447 (2002) 227-237
23. McCormick D.A., and Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 63 (2001) 815-846
24. Aronica E., Yankaya B., Troost D., van Vliet E.A., da Silva F.L., and Gorter J.A. Induction of neonatal sodium channel II and III α-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur J Neurosci 13 (2001) 1261-1266
25. Klein J.P., Khera D.S., Nersesyan H., Kimchi E.Y., Waxman S.G., and Blumenfeld H. Dysregulation of sodium channel expression in cortical neurons in a rodent model of absence epilepsy. Brain Res 1000 (2004) 102-109
26. Blumenfeld H., Lampert A., Klein J.P., et al. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia 50 (2009) 44-55
27. Ketelaars S.O., Gorter J.A., van Vliet E.A., da Silva F.L., and Wadman W.J. Sodium currents in isolated rat CA1 pyramidal and dentate granule neurones in the post-status epilepticus model of epilepsy. Neuroscience 105 (2001) 109-120
28. Whitaker W.R., Faull R.L., Dragunow M., Mee E.W., Emson P.C., and Clare J.J. Changes in the mRNAs encoding voltage-gated sodium channel types II and III in human epileptic hippocampus. Neuroscience 106 (2001) 275-285
29. Agrawal N., Alonso A., and Ragsdale D.S. Increased persistent sodium currents in rat entorhinal cortex layer V neurons in a post-status epilepticus model of temporal lobe epilepsy. Epilepsia 44 (2003) 1601-1604
30. Vreugdenhil M., Hoogland G., van Veelen C.W., and Wadman W.J. Persistent sodium current in subicular neurons isolated from patients with temporal lobe epilepsy. Eur J Neurosci 19 (2004) 2769-2778
31. Kearney J.A., Plummer N.W., Smith M.R., et al. A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience 102 (2001) 307-317
32. Meisler M.H., and Kearney J.A. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 115 (2005) 2010-2017
33. Mulley J.C., Scheffer I.E., Petrou S., Dibbens L.M., Berkovic S.F., and Harkin L.A. SCN1A mutations and epilepsy. Hum Mutat 25 (2005) 535-542
34. Harkin L.A., McMahon J.M., Iona X., et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130 (2007) 843-852
35. Avanzini G., Franceschetti S., and Mantegazza M. Epileptogenic channelopathies: experimental models of human pathologies. Epilepsia 48 suppl 2 (2007) 51-64
36. Berkovic S.F., Heron S.E., Giordano L., et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol 55 (2004) 550-557
37. + channel causing benign familial neonatal-infantile seizures. J Neurosci 26 (2006) 10100-10109
38. v1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc Natl Acad Sci USA 102 (2005) 18177-18182
39. Scheffer I.E., and Berkovic S.F. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 120 (1997) 479-490
40. Dravet C., Bureau M., Oguni H., Fukuyama Y., and Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol 95 (2005) 71-102
41. Claes L., Del Favero J., Ceulemans B., Lagae L., Van Broeckhoven C., and De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68 (2001) 1327-1332
42. + phenotypes associated with SCN1B mutations. Brain 130 (2007) 100-109
43. Xu R., Thomas E.A., Gazina E.V., et al. Generalized epilepsy with febrile seizures plus-associated sodium channel β1 subunit mutations severely reduce beta subunit-mediated modulation of sodium channel function. Neuroscience 148 (2007) 164-174
44. Patino G.A., Claes L.R., Lopez-Santiago L.F., et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 29 (2009) 10764-10778
45. Singh N.A., Pappas C., Dahle E.J., et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 5 (2009) e1000649
46. Lossin C. A catalog of SCN1A variants. Brain Dev 31 (2009) 114-130
47. George Jr. A.L. Inherited disorders of voltage-gated sodium channels. J Clin Invest 115 (2005) 1990-1999
48. v1.1 sodium channels cause epilepsy?. Brain Res Rev 58 (2008) 149-159
49. Tang B., Dutt K., Papale L., et al. A BAC transgenic mouse model reveals neuron subtype-specific effects of a generalized epilepsy with febrile seizures plus (GEFS+) mutation. Neurobiol Dis 35 (2009) 91-102
50. + channel mutant. J Neurosci 27 (2007) 11037-11046
51. v1.1 (SCN1A) sodium channel mutant causes GEFS+: common mechanism in Nav1.1 related epilepsies?. Hum Mutat 30 (2009) E747-E760
52. Yu F.H., Mantegazza M., Westenbroek R.E., et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9 (2006) 1142-1149
53. Oakley J.C., Kalume F., Yu F.H., Scheuer T., and Catterall W.A. Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy. Proc Natl Acad Sci USA 106 (2009) 3994-3999
54. v1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 27 (2007) 5903-5914
55. Xu R., Thomas E.A., Jenkins M., et al. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel. Mol Cell Neurosci 35 (2007) 292-301
56. Dichgans M., Freilinger T., Eckstein G., et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366 (2005) 371-377
57. Gargus J.J., and Tournay A. Novel mutation confirms seizure locus SCN1A is also familial hemiplegic migraine locus FHM3. Pediatr Neurol 37 (2007) 407-410
58. + channel. J Neurosci 28 (2008) 7273-7283
59. Kahlig K.M., Rhodes T.H., Pusch M., et al. Divergent sodium channel defects in familial hemiplegic migraine. Proc Natl Acad Sci USA 105 (2008) 9799-9804
60. Hadjikhani N., Sanchez D.R., Wu O., et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 98 (2001) 4687-4692
61. Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics 4 (2007) 274-284
62. Bolay H., Reuter U., Dunn A.K., Huang Z., Boas D.A., and Moskowitz M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8 (2002) 136-142
63. Iwata A., Stys P.K., Wolf J.A., et al. Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors. J Neurosci 24 (2004) 4605-4613
64. + current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J Physiol 563 (2005) 843-854
65. Pieri M., Carunchio I., Curcio L., Mercuri N.B., and Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol 215 (2009) 368-379
66. + conductances and neurodegeneration in amyotrophic lateral sclerosis. Exp Neurol 218 (2009) 1-4
67. Craner M.J., Damarjian T.G., Liu S., et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49 (2005) 220-229
68. Cummins T.R., and Rush A.M. Voltage-gated sodium channel blockers for the treatment of neuropathic pain. Expert Rev Neurother 7 (2007) 1597-1612
69. Yang Y., Wang Y., Li S., et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 41 (2004) 171-174
70. v1.7 sodium channels in a painful inherited neuropathy. J Neurosci 24 (2004) 8232-8236
71. Fertleman C.R., Baker M.D., Parker K.A., et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52 (2006) 767-774
72. Cox J.J., Reimann F., Nicholas A.K., et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444 (2006) 894-898
73. Pertin M., Ji R.R., Berta T., et al. Upregulation of the voltage-gated sodium channel β2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci 25 (2005) 10970-10980
74. + channels and central pain. Trends Neurosci 29 (2006) 207-215
75. v 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. J Pain 5 (2004) 270-280
76. V1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain 12 (2008) 564-572
77. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 (2004) 553-564
78. + channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic and anticonvulsant drugs. Mol Pharmacol 40 (1991) 756-765
79. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16 (2002) 669-694
80. Poolos N.P., Migliore M., and Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 5 (2002) 767-774
81. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307 (1996) 113-116
82. Zona C., Tancredi V., Longone P., et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia 43 (2002) 685-690
83. Shank R.P., and Maryanoff B.E. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 14 (2008) 120-142
84. Gryder D.S., and Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23 (2003) 7069-7074
85. Qian J., and Noebels J.L. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res 55 (2003) 225-233
86. Crunelli V., and Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci 3 (2002) 371-382
87. Coulter D.A., Huguenard J.R., and Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 25 (1989) 582-593
88. Leresche N., Parri H.R., Erdemli G., et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J Neurosci 18 (1998) 4842-4853
89. Pittenger C., Coric V., Banasr M., Bloch M., Krystal J.H., and Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22 (2008) 761-786
90. Curia G., Biagini G., Perucca E., and Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 23 (2009) 555-568
91. Errington A.C., Stohr T., Heers C., and Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73 (2008) 157-169
92. Errington A.C., Coyne L., Stohr T., Selve N., and Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50 (2006) 1016-1029
93. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10 (2004) 685-692
94. Ettinger A.B., and Argoff C.E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4 (2007) 75-83
95. Calabresi P., Galletti F., Rossi C., Sarchielli P., and Cupini L.M. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 28 (2007) 188-195
96. Calabresi P., Cupini L.M., Centonze D., Pisani F., and Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol 53 (2003) 693-702
97. Pitkanen A. Efficacy of current antiepileptics to prevent neurodegeneration in epilepsy models. Epilepsy Res 50 (2002) 141-160
98. Kapoor R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 274 (2008) 54-56
99. Spain R.I., Cameron M.H., and Bourdette D. Recent developments in multiple sclerosis therapeutics. BMC Med 7 (2009) 74
100. Kapoor K., Furby J., and Hayton T. Outcomes of a phase II randomized controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis. Mult Scler 15 suppl 2 (2009) 27
101. Urbani A., and Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 12 (2000) 3567-3574
102. Lai J., Porreca F., Hunter J.C., and Gold M.S. Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 44 (2004) 371-397
103. Cruccu G. Treatment of painful neuropathy. Curr Opin Neurol 20 (2007) 531-535
104. Beyreuther B.K., Freitag J., Heers C., Krebsfanger N., Scharfenecker U., and Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 13 (2007) 21-42
105. Fertleman C.R., Ferrie C.D., Aicardi J., et al. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology 69 (2007) 586-595
106. v1.7 and human pain disorders. Trends Neurosci 30 (2007) 555-563
107. Fischer T.Z., Gilmore E.S., Estacion M., et al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol 65 (2009) 733-741
108. Martin M.S., Tang B., Papale L.A., Yu F.H., Catterall W.A., and Escayg A. The voltage-gated sodium channel Scn8a is a genetic modifier of severe myoclonic epilepsy of infancy. Hum Mol Genet 16 (2007) 2892-2899
109. Catterall W.A., Cestele S., Yarov-Yarovoy V., Yu F.H., Konoki K., and Scheuer T. Voltage-gated ion channels and gating modifier toxins. Toxicon 49 (2007) 124-141
110. Trudeau M.M., Dalton J.C., Day J.W., Ranum L.P., and Meisler M.H. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet 43 (2006) 527-530
111. London C., Hoyt S.B., Parsons W.H., et al. (2008). Imidazopyridines: a novel class of hNav1.7 channel blockers. Bioorg Med Chem Lett 18 (2008) 1696-1701
112. V1.8 and has a long-lasting analgesic activity. Biochemistry 45 (2006) 7404-7414
113. v1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci USA 103 (2006) 17030-17035